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Abstract  
 Drug delivery to the central nervous system is complicated by the blood brain barrier, a 
vascular structure that prevents free diffusion of molecules into brain tissue.  In this study, we 
examined the in vitro properties of a nanoparticle-based drug delivery system. We used several 
nanoparticle formulations, both LTP based and PLGA based, to test the cellular uptake and 
toxicity in microglial cells. Using immunofluorescence imaging, we show that LTP nanoparticles 
are taken up by microglia. We confirmed that our nanoparticle formulations are nontoxic by two 
cell viability assays. These results suggest that nanoparticle formulations may be a biocompatible 
method of delivering drugs to the brain. 
 
Introduction  
 Drug delivery to the central nervous system (CNS) is a challenging goal that hinders the 
development of new therapeutics as well as imaging agents. A major difficulty for drug targeting 
to the brain is the presence of a specialized vascular structure termed the blood-brain barrier 
(BBB). The BBB is composed of endothelial cells that express tight junction proteins and inhibit 
the free diffusion of small molecules from the blood to the brain.2 These cells also express ATP-
dependent transporters that remove xenobiotics from the brain.1 Due to the need to overcome this 
unique barrier, the physiochemical characteristics of drug formulations that successfully 
penetrate the brain endothelium and accumulate in the parenchyma have been extensively 
investigated. Compounds that are ligands for specific receptors expressed on the BBB as well as 
lipophilic compounds and some gases are able to readily penetrate into the brain parenchyma.2  
 A current area of active investigation for drug delivery is the packaging of compounds 
into nanoparticle formulations. Polymeric protein-based nanoparticles are being studied for 
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biomedical applications, such as MRI imaging and drug delivery.3  The main goal of this study 
was to test a nanoparticle delivery system for imaging agents and anti-inflammatory drugs that 
would increase CNS uptake. We focused on designing nanoparticle formulations that would not 
only penetrate the BBB, but also exhibit an affinity for microglia. Microglial cells are considered 
the major component of the immune system present within the CNS. These cells are 
multifunctional and can constantly scan the brain for damaged cells, debris and other indicators 
of trauma.4 Once the microglia sense injury or infection they will become activated (Figure 1). 
In an activated state, they promote wound healing via phagocytosis of debris and activate other 
immune cells via release of cytokines, such as transforming growth factor beta (TGF-β).2 
Activation of microglial cells occurs early after injury and this response is characteristics of a 
number of neurodegenerative and inflammatory conditions such as traumatic brain injury, 
Alzheimer’s, and Parkinson’s disease.5 
 
 
Figure 1: Microglial activation results from cytokine signaling and leads to release of pro-
inflammatory (M1) or anti-inflammatory (M2) activity. 
 Recently, it has been shown that phagocytic cells such as macrophages can take up 
nanoparticles and deliver them through the BBB.6  We hoped to exploit the natural phagocytotic 
phenotype of the microglia in a similar strategy to induce uptake of our nanoparticles. A second 
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motivation for targeting microglial cells is that their early activation and differentiation into pro-
inflammatory cells make them ideal targets for an anti-inflammatory compound.2 The 
nanoparticle formulations that we test in this study consists of either a modified L-Tyrosine 
phosphate (LTP) monomer or poly(lactic-co-glycolic acid) (PLGA) (Figure 2). LTP was chosen 
due to a polyethylene glycol (PEG) coating that allows for greater systemic distribution.7 Both 
formulations have also been shown to be non-toxic.7,8 Compounds were subsequently loaded into 
the nanoparticle formulations to test delivery and toxicity. The imaging agent Gadolinium-
Diethylenetriaminepentaacetic acid (Gd-DTPA), was incorporated into particles and examined 
for toxicity. Gd-DPTA (Figure 2) is an FDA-approved contrast agent for MRI. Gd-based 
contrast agents allow visualization of areas of blood brain breakdown and are used to detect 
inflammatory lesions in the CNS.9 In addition, the same polymer nanoparticles were tested 
uptake by confocal imaging. For these experiments, the particles contained BSA conjugated to 
the fluorophore FITC. The PLGA nanoparticle formulation was loaded with the anti-
inflammatory drug Rolipram. Rolipram acts by inhibiting phosphodiesterase IV subtype, PDE 
IVB, increasing intracellular levels of cAMP that leads to suppression of CNS inflammatory 
responses.10 
 
Figure 2: Structures of modified L-Tyrosine Phosphate (LTP), poly(lactic-co-glycolic acid) 
(PLGA) monomer, chelated gadolinium and rolipram. All structures were drawn using 
ChemDoodle software.  
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A microglia-like cell line, SIMA9, was used to test the biocompatibility of these particles. 
SIMA9 cells respond to inflammatory stimulation similar to primary microglial cells, providing a 
method of testing on primary microglia without the harvesting process.11  
We found that SIMA9 cells readily internalized nanoparticles.  In addition, the 
formulations displayed limited toxicity even at high concentrations.  Finally, we sought to 
measure whether nanoparticle uptake could trigger release of pro-inflammatory cytokines from 
cells, but we were unable to make a solid conclusion about cytokine release from our results.  
   
Materials and Methods  
Nanoparticle Synthesis and Characterization  
The LPS and PLGA nanoparticles used in this study were synthesized by the Yun lab in 
Biomedical Engineering as previously described by using an oil and water emulsion via 
sonication and evaporation.12 Physical characteristics of the nanoparticle, such as size and 
morphology, were then determined via scanning electron microscopy and dynamic laser light 
scattering.12  
Cell Culture  
All cells were cultured at 37°C and 5% CO2 in DMEM media with 5% horse serum and 10% 
fetal bovine serum.  Approximately every 4 days, a standard protocol for splitting adherent cells 
was used with minor additions for SIMA9 cells as they are semi-adherent. To account for the 
semi-adherence, all PBS wash steps were eliminated. Cell counting using a hemocytometer was 
also used to determine seed density for plates used in these experiments.  
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Immunofluorescence  
In order to determine the uptake of nanoparticles by SIMA9 cells, confocal imaging was 
performed. Cells were plated at 105 cells/well on coverslips coated in poly-L-lysine, which was 
used to account for the semi-adherence of the cells as it acts as a synthetic attachment factor.13 
Cells were subsequently treated with 20 µg/mL or 200 µg/mL of nanoparticle (LTP BSA-FITC) 
and left to incubate overnight (See Table 1 for plate set-up). If the cells were also being treated 
with LPS (100 ng/mL), this was done 24 hours prior to nanoparticle exposure. The cells were 
then fixed using 4% paraformaldehyde, blocked with 10 % FBS, and incubated with anti-F480 
antibody conjugated to eFluro 570 (Texas Red) at a concentration of 5 µg/mL.  
Determination of Cell Viability  
To test the potential cytotoxicity of the nanoparticle two cell viability assays were used, the 
Thiazolyl Blue Tetrazolium Bromide (MTT) Assay (ThermoFisher Scientific) and a resazurin 
assay were performed. Spectrophotometry is used along with this assay to quantify MTT color 
change.14. Details on the nanoparticle treatments are given in Table 1. The absorbance of the 
plate was read at 590 nm. For each of the treatments, percent viability was calculated using the 
treatment mean divided by the control mean times 100. 
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Table 1: Detailed method for the preparation of nanoparticle solutions for MTT and resazurin 
assay treatment. 
well #  1 2 3 4 5 6 7 8 9 10 11 12 
Stock 
(ug/mL) 5000         2500 1000 500 100 50 50 10 
vol stock 
(uL) 100 50 20 15 10 10 10 10 10 10 5 10 
final conc 
(ug/mL) 5000 2500 1000 750 500 250 100 50 10 5 2.5 1 
final 
volume 
(uL) 100 100 100 100 100 100 100 100 100 100 100 100 
vol PBS 
(uL)   50 80 85 90 90 90 90 90 90 95 90 
treatment 
(µL) 10 10 10 10 10 10 10 10 10 10 10 10 
 
 A resazurin assay was subsequently used because the MTT assay involved removing the 
media before testing and likely disrupted the cells, giving inconsistent results due to the semi-
adherent nature of SIMA9 cultures. This resazurin assay involves using resazurin dye, which is 
reduced by metabolically active cells. This reduction visibly changes the dye from blue to red, 
which can be measured by spectrophotometric methods.15 This assay does not involve removing 
any media and does not have any wash steps, which was ideal for the semi-adherent cell line.  
 The protocol for the In Vitro Toxicology Assay Kit; Resazurin Based, from Sigma 
Aldrich, was used.15 The SIMA9 cells were plated on a 96-well plate and left to incubate 
overnight (see Appendix B for plate set up). Cells were treated with a range of concentrations of 
PLGA and PLGA-Rolipram nanoparticles (Table 2). After a second 24-hour incubation, each 
well was treated with 10 µL of resazurin dye solution and incubated for 4 hours. The plate was 
then read for fluorescence at 590 nm. The fluorescence was corrected for by using the 
fluorescent reading of PBS subtracted from the average fluorescence reading for each treatment 
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of the two nanoparticles. This value was then divided by the fluorescence of PBS and multiplied 
by 100 to obtain % viability.  
Table 2: Detailed method for the preparation of nanoparticle solutions for the Resazurin-based 
cell viability assay.   
Well #    1 2 3 4 5 67 8 9 10 11 12 
Stock (ug/mL) 5000       2500 1000 500 500 100 50 10 10 
vol stock (uL) 100 50 20 10 10 10 10 5 10 10 10 5 
final conc 
(ug/mL) 5000 2500 1000 500 250 100 50 25 10 5 1 0.5 
final volume (uL) 100 100 100 100 100 100 100 100 100 100 100 100 
vol PBS (uL)   50 80 90 90 90 90 95 90 90 90 95 
 
 
Quantification of Cytokine Release after Nanoparticle Treatment 
To measure cytokine release by SIMA9 cells after nanoparticle treatment, an enzyme-linked 
immunosorbent assay, or ELISA, was used. ELISA uses an enzymatic assay to determine the 
relative abundance of a particular protein in a sample.16 An ELISA was done on two different 
samples of SIMA9 cells that were treated with either a PLGA formulation or a PLGA-Rolipram 
formulation (each at 20 µg/mL) in the presence or absence of LPS (100 g/mL). The media from 
these treated cells was collected and used in a 96-well plate set up (Appendix B).  For the 
ELISA, the protocol from Affymetrix eBioscience ELISA kit was followed.17  
 
Results and Discussion  
 We first examined the uptake and internalization of our nanoparticle formulations in 
SimA9 cells.  Cultures were treated with nanoparticles containing BSA-FITC in the presence and 
absence of the immune stimulator LPS, a bacterial product that induces a pro-inflammatory M1 
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phenotype in these cells. Resting cells showed evidence of nanoparticle uptake and this was not 
accompanied by changes in activation state such as alterations in membrane morphology (Figure  
3A-B). The treatment with nanoparticle and LPS also displayed nanoparticle uptake; however, 
there was evidence of microglial activation due to LPS stimulation.  Prominent membrane 
protrusions are observed on the microglia and this indicates the cells are activated and 
internalizing the nanoparticles (Figure 3C). While activation altered the shape of the 
nanoparticles, there did not appear to be an increase in the amount of nanoparticles internalized, 
although quantification would be necessary to definitively determine this. 
 
Figure 3: SIMA9 cells internalize polymeric nanoparticles. A) control SIMA9 containing no 
nanoparticle, no LPS). Blue stain is DAPI (nucleus) and red stain is anti F480 (SIMA9/microglia 
surface marker). B) SIMA9 cells treated with BSA-FITC nanoparticle (20 µg/mL for 24 hours).. 
The yellow dots are BSA-FITC nanoparticles. C) SIMA9 cells treated with BSA-FITC 
nanoparticle (20 µg/mL for 24 hours) after treatment with LPS (100 ng/mL for 24 hours). 
Magnification is 60X. 
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 To determine potential cytotoxicity of the nanoparticle formulations, MTT assays were 
performed. MTT is a common assay used to determine cell viability.  In this assay, MTT will 
react and undergo a color change (reduction) when it encounters oxidoreductase enzymes that 
are NADH dependent. Because the presence of these enzymes indicates NADH levels, the MTT 
reduction can be used to determine metabolic activity.14 The results of the two MTT experiments 
are shown in Figures 4 and 5.  SIMA9 cells were treated with increasing concentrations of two 
different nanoparticle formulations for 24 hours followed by viability measurements.  
 In the first MTT assay, it appears that there is no correlation between the amount of 
viable cells and the concentration of nanoparticle in the treatment (Figure 4A, B). In addition, 
some of the treatment groups had over 100% viability.   We performed a second assay to 
determine the reproducibility. However, the second MTT assay (Figure 5A, B) not only shows 
no correlation between treatment concentration and percent viability but also yielded different 
values. In the second MTT there were also several values for percent viability for the Gd-DTPA 
nanoparticle that were over 100%. However, this could indicate that the cells proliferated during 
the assay. Because these two assays yielded different results, it cannot be determined if there is 
or is not a correlation between viability and concentration. However, it appears that the 
nanoparticles do not cause significant cytotoxic effects as almost all the treatments across the 
two trials show % viability over 80%. This is consistent with previous research on the 
biocompatibility of these nanoparticles.6,7 
 One possible explanation for the variability of these MTT assays is the protocol of the 
assay calls for the tissue culture medium to be removed and samples are washed for several wash 
steps. As SIMA9 cells are semi-adherent, these methods likely disturb the cells, which may be 
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the reason that there was no consistent trend of viability as some wells had more cells 
undisturbed than others. 
 
 
Figure 4: Viability of SIMA9 cells treated with polymeric nanoparticles. Results from the first 
MT with MTT assay.  Cells were treated with increasing concentrations of Gd-DTPA loaded 
LTP nanoparticles (A) or BSA-FITC LTP nanoparticles (B) for 24 hours followed by MTT 
assay. N = 3 per treatment. 
 
 
 
 
 
 
A 
B 
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Figure 5:  Viability of SIMA9 cells after LTP nanoparticle treatment.  MTT was repeated to 
measure toxicity of Gd-loaded nanoparticles.  Cultures of SIMA9 cells were treated with 
increasing concentrations of Gd-DPTA particles (A) or BSA-FITC LTP nanoparticles (B) and 
viability was measured after a total of 24 hours of treatment by MTT.  N = 3 per treatment. 
 To obtain more reliable results, a resazurin-based cytotoxicity assay was used. In this 
assay, a reduction of resazurin causes a color change from blue to red, which indicates 
metabolically active cells.15 The fluorescence of the plate was read at 590 nm and the resulting 
values were corrected and converted to % viability. The results of this assay are shown in Figure 
6.  Based on the results of the resazurin-based assay, it is difficult to determine a pattern between 
concentration of nanoparticle in the treatment and cell viability. In the PLGA treatment, the % 
viability did not correlate with amount of treatment. However, it also does not appear that PLGA 
A 
B 
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has a significant effect on the overall viability of the cells as the lowest % viability value was 
near 77%, which corresponded to a treatment of .005 µg/mL. These results are similar to our 
LTP nanoparticle formulations. Because this treatment is nearly negligible, it is likely that this 
low viability can be attributed to an inaccurate cell concentration (cells/well). This could also 
explain the % viability values over 100%. While the PLGA-Rol nanoparticles still did not 
display a correlation between cell viability and treatment concentration, the results were more 
consistent than those of PLGA. They also showed higher % viability values overall, so based on 
these data the PGLA-Rol nanoparticle do not affect cell viability. Overall, these results indicate 
that these two nanoparticle formulations are likely not cytotoxic to microglia-like cells, which 
again confirms what has been shown in previous studies.6,7 
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Figure 6: Viability of SIMA9 cells after PLGA-Rol nanoparticle treatment.  Resazurin-based 
assay was used to measure toxicity of Rolipram-loaded nanoparticles.  Cultures of SIMA9 cells 
were treated with increasing concentrations of PLGA particles (A) or PLGA-Rol nanoparticles 
(B) and viability was measured after a total of 24 hours of treatment by resazurin.  N = 3 per 
treatment. 
 
 To determine if the nanoparticle causes activation of the microglia, an ELISA was 
performed to measure release of the pro-inflammatory cytokine, tumor necrosis factor (TNF).  
TNF can be released by microglia upon activation to a pro-inflammatory M1 phenotype and will 
result in activation of other immune cells in to promote inflammation.4 To use these 
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nanoparticles to treat inflammatory CNS diseases, the formulation should not induce an 
inflammatory response by itself. This would indicate that the microglia are activated by the 
nanoparticle and it cannot be used as a delivery system for contrast agent detect early activation 
of microglia.  
 The optical density, measured at 450 nm, was subsequently used to determine the 
concentration of TNF-α in the samples, by constructing a standard curve using known 
concentrations of TNF-α stock solutions (see materials and methods and Figure 7).  Using this 
curve, the average absorbance readings of standards were converted to concentrations (see Table 
3) by using the Beer-Lambert Law.18 In addition to averages for each treatment, the standard 
deviation was also calculated to determine the coefficient of variation percentage, CV%. The 
higher this value is, the more variation has occurred in the data, meaning there is greater 
inconstancy.  
 
Figure 7: Standard curve of known concentrations of TNF-.  Protein concentrations ranged 
from 7.8 pg to 1000 pg.  
 Because the standard curve generated from this ELISA was not linear, the calculated 
values for concentration of TNF-α cannot be used to make any conclusions about nanoparticle 
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activation. The error in the standard curve can be attributed to inaccurate pipetting as well as 
potential contamination during wash steps. While no conclusions about nanoparticle activation of 
microglia were made from the ELISA, the immunofluorescence images show that the cells 
treated with only nanoparticles did not display morphology of activation as the cells treated with 
LPS. This could indicate that the nanoparticle does not cause microglial activation upon uptake. 
This would further support the role of these nanoparticles as drug delivery agents. A potential 
future study could look at nanoparticle uptake in primary glia to determine if nanoparticle uptake 
is specific to microglia when compared to all glial cells.  
 
Conclusions  
The goal of this study was to determine the potential use of nanoparticles as a CNS drug delivery 
system by observing nanoparticle uptake, cytotoxicity and cytokine release upon uptake. Overall, 
the result support that the nanoparticle is taken up by microglia-like cells and is likely not toxic, 
which is in support of previous studies.5,6,7 These data do not confirm or deny potential 
activation of microglia due to nanoparticle uptake as no conclusions could be drawn from the 
ELISA. More conclusions could be drawn if a repeat ELISA was performed. Further 
experimentation on the effects of different nanoparticle formulations as well as determination of 
preferential uptake of nanoparticle by microglia could help give a more complete understanding 
of the effectiveness of nanoparticles as drug delivery systems for the CNS.   
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Appendix A- Safety Considerations  
 
 Precautions were taken to ensure safety during all steps of this experiment. Nitrile gloves 
were worn at all times to avoid contact of any cells/media with the skin. Any piece of equipment 
that encountered cells and/or media was discarded in a biohazard waste container. All 
cells/media were handled under a laminar flow hood. With each use of the laminar flow hood, 
70% ethanol was used to wipe down the hood surface to maintain a sterile environment. All 
pipets were placed in a disposal container after use. All work in the lab was done under the 
supervision of a graduate student.  
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Appendix B- Experimental Plate Set-Ups 
 
 
 
Table B1: Plate set up for Resazurin-based cell viability assay. In each of the three-well controls, 
no assay indicates that no resazurin was used and assay only means resazurin was added. 
 
 
Table B2: Plate set up for ELISA using PLGA and PLGA-Rolipram nanoparticle formulations. 
The light blue area represents the media from cells treated with the indicated treatments of 
PLGA and the dark pink area represents the media from cells treated with the indicated 
treatments of PLGA-Rolipram. 
 
 
 
